Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor Decision- Financial Considerations
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NF (Naltrexone+Fluoxetine) | Experimental | Naltrexone SR 32 mg and fluoxetine 60 mg |
|
| Fluoxetine | Active Comparator | Fluoxetine 60 mg |
|
| Naltrexone | Active Comparator | Naltrexone SR 32 mg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fluoxetine 60 mg | Drug | Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the mean change from baseline to Week 10 in total Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score between the combination treatment group versus fluoxetine alone and naltrexone SR alone | Baseline to Week 10 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeffrey T Apter, MD, PA | Global Medical Institutes, LLC | Principal Investigator |
| Ward Smith, MD | Summit Research Network, Inc. | Principal Investigator |
| Vishaal Mehra, MD | California Clinical Trials | Principal Investigator |
| Naresh P Emmanuel, MD | Carolina Clinical Research Services | Principal Investigator |
| Mohammad Bari, MD | Synergy Clinical Research | Principal Investigator |
| Robert Riesenberg, MD | Atlanta Center for Medical Research | Principal Investigator |
| Teresa Pigott, MD | University of Florida, Dept Of Psychiatry | Principal Investigator |
| Andrew W Goddard, MD | Indiana University | Principal Investigator |
| Al Rivera, MD | Community Research | Principal Investigator |
| Jeffrey S Simon, MD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Synergy Clinical Research | National City | California | 91950 | United States | ||
| California Clinical Trials |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Naltrexone 32 mg and fluoxetine 60 mg | Drug | Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg. |
|
| Naltrexone SR 32 mg | Drug | Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy. |
|
| Northbrooke Research Center |
| Principal Investigator |
| Zinoviy Benzar, MD | Brooklyn Medical Institute | Principal Investigator |
| San Diego |
| California |
| 92123 |
| United States |
| University of Florida, Department of Psychiatry | Gainesville | Florida | 32606 | United States |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | United States |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | United States |
| Global Medical Institute, LLC | Princeton | New Jersey | 08540 | United States |
| Brooklyn Medical Institute | Brooklyn | New York | 11223 | United States |
| Community Research | Cincinnati | Ohio | 45227 | United States |
| Summit Research Network, Inc. | Portland | Oregon | 97210 | United States |
| Carolina Clinical Research Services | Columbia | South Carolina | 29201 | United States |
| Northbrooke Research Center | Brown Deer | Wisconsin | 53223 | United States |
| ID | Term |
|---|---|
| D009771 | Obsessive-Compulsive Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D005473 | Fluoxetine |
| D009271 | Naltrexone |
| ID | Term |
|---|---|
| D011437 | Propylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009270 | Naloxone |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided